Atossa Genetics Announces Intraductal Microcatheter ImmunoOncology Pre-Clinical Program
July 18 2018 - 8:00AM
Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a
clinical-stage biopharmaceutical company developing novel
therapeutics and delivery methods to treat breast cancer and other
breast conditions, today announced that it is advancing its
intraductal microcatheter immunotherapy program with pre-clinical
studies being conducted by Translational Drug Development, LLC
(“TD2”). The purpose of the initial study is to develop and
validate preclinical methods of using Atossa’s proprietary
intraductal microcatheter technology to administer immunotherapy to
the site of tumor initiation.
“While there has been recent success treating blood cancers with
chimeric antigen receptor therapy (or, CAR-T), there has not been
much success using CAR-T to treat solid tumors like breast cancer,”
commented Steve Quay, Ph.D., MD, President and CEO of Atossa. “We
are, however, encouraged by a recent case study reported June 4,
2018 in Nature Medicine (N. Zacharakis, et al.), in which a patient
with metastatic breast cancer who was not responding to
chemotherapy had complete tumor regression 22 months after being
treated with an intravenous infusion of eighty billion T-cells and
interleukin. We believe our proprietary intraductal microcatheter
technology may provide a unique and more efficacious and
cost-effective treatment method by delivering a significantly
smaller number of T-cells directly to the site of the cancer prior
to metastasis, rather than through the blood stream, where they are
diluted into the entire body. These studies are the first of
several steps to develop our intraductal microcatheter technology
to treat breast cancer with cell-based immunotherapy, such as
CAR-T. These pre-clinical studies will form the basis for the
design of human studies, with the ultimate goal of treating breast
cancer by administering an immunotherapy with our proprietary
microcatheter technology,” added Dr. Quay.
The studies are being conducted for Atossa by Translational Drug
Development, LLC, which is an oncology development organization
that provides innovative services and is uniquely positioned to
support improved and accelerated development of medicines for
life-threatening oncology diseases.
About Atossa Genetics
Atossa Genetics Inc. is a clinical-stage pharmaceutical company
developing novel therapeutics and delivery methods to treat breast
cancer and other breast conditions. For more information, please
visit www.atossagenetics.com.
About TD2
TD2 supports oncology-focused companies by providing a unique
and translational set of services to accelerate drug
development. Using a dedicated team of professionals with
broad experience and understanding in drug development, TD2 applies
thorough and high-throughput translational preclinical development,
combined with regulatory affairs expertise, to customize clinical
trial design and execution. For more information, visit
www.TD2inc.com.
Forward-Looking Statements
Forward-looking statements in this press release, which Atossa
undertakes no obligation to update, are subject to risks and
uncertainties that may cause actual results to differ materially
from the anticipated or estimated future results, including the
risks and uncertainties associated with any variation between
preliminary and final clinical results, actions and inactions by
the FDA, the outcome or timing of regulatory approvals needed by
Atossa including those needed to commence studies, lower than
anticipated rate of patient enrollment, estimated market size of
drugs under development, the safety and efficacy of Atossa's
products and services, performance of clinical research
organizations and investigators, obstacles resulting from
proprietary rights held by others with respect to fulvestrant, such
as patent rights, potential market sizes for Atossa’s drugs under
development and other risks detailed from time to time in Atossa's
filings with the Securities and Exchange Commission, including
without limitation its periodic reports on Form 10-K and 10-Q, each
as amended and supplemented from time to time.
Atossa Genetics Company Contact:
Atossa Genetics Inc.Kyle GuseCFO and General
Counsel(O) 866 893-4927kyle.guse@atossagenetics.com
Investor Relations Contact:
Scott GordonCoreIR377 Oak StreetConcourse
2Garden City, NY 11530Office: 516 222-2560scottg@CoreIR.com
Source: Atossa Genetics Inc.
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Apr 2023 to Apr 2024